Literature DB >> 17503339

Lymphatic and blood vessel morphometry in invasive breast carcinomas: relation with proliferation and VEGF-C and -D proteins expression.

E Mylona1, A Nomikos, P Alexandrou, I Giannopoulou, A Keramopoulos, L Nakopoulou.   

Abstract

INTRODUCTION: The aim of the present study was to investigate the distribution of both lymphatics and blood microvessels in invasive breast carcinomas and the clinicopathological and prognostic significance of their density and size related parameters as well as their correlation with the proliferative potential of the tumor and VEGF-C and -D expression.
METHODS: Both single and double immunohistochemistry were applied on a series of 146 paraffin-embedded breast tissue specimens to detect VEGF-C and -D as well as lymphatics and blood microvessels, respectively. Computer-assisted morphometry was performed to evaluate the blood and lymphatic vessel density (BVD and LVD respectively) as well as various vascular size related parameters.
RESULTS: Lymphatics were detected within the stroma at the tumor border, while blood vessels were located in both the interior of the tumor mass and peritumor stroma. BV major axis, minor axis and perimeter inversely correlated with ER (p=0.011, p=0.023 and p=0.008 respectively), while LV major axis, minor axis and the perimeter inversely correlated with tumor nuclear grade (p=0.045, p=0.037 and p=0.032 respectively) and topoisomerase IIalpha (p=0.015, p=0.024 and p=0.045 respectively). The same LV parameters were found to positively correlate with cancerous VEGF-C (p<0.0001, p=0.092 and p=0.012 respectively) and VEGF-D in the stromal fibroblasts surrounding neoplastic cells (p=0.011, p=0.041 and p=0.026 respectively). High BVD exerted an unfavorable impact on both disease-free (p=0.021) and overall survival (p=0.031) of the patients. High LVD correlated with poor disease-free and overall survival only in the subgroup of patients with ER-negative tumors (p=0.056 and p=0.0312 respectively).
CONCLUSION: These findings, for the first time, correlate lymphatic size with tumors of limited proliferative potential and higher nuclear differentiation. Moreover, they suggest that VEGF-C and -D expression influence lymphatic size rather than being involved in the increase of lymphatic vessel number.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503339     DOI: 10.14670/HH-22.825

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  12 in total

1.  Oregano demonstrates distinct tumour-suppressive effects in the breast carcinoma model.

Authors:  Peter Kubatka; Martin Kello; Karol Kajo; Peter Kruzliak; Desanka Výbohová; Ján Mojžiš; Marián Adamkov; Silvia Fialová; Lucia Veizerová; Anthony Zulli; Martin Péč; Dagmar Statelová; Daniel Grančai; Dietrich Büsselberg
Journal:  Eur J Nutr       Date:  2016-02-23       Impact factor: 5.614

2.  Can lymphatic vascular density be used in determining metastatic spreading potential of tumor in invasive ductal carcinomas?

Authors:  Nilufer Onak Kandemir; Figen Barut; Sibel Bektas; Sukru Oguz Ozdamar
Journal:  Pathol Oncol Res       Date:  2011-07-23       Impact factor: 3.201

Review 3.  Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature.

Authors:  Jun Wang; Yan Guo; Baocheng Wang; Jingwang Bi; Kainan Li; Xiuju Liang; Huili Chu; Huihui Jiang
Journal:  Mol Biol Rep       Date:  2012-10-11       Impact factor: 2.316

4.  Antineoplastic effects of clove buds (Syzygium aromaticum L.) in the model of breast carcinoma.

Authors:  Peter Kubatka; Sona Uramova; Martin Kello; Karol Kajo; Peter Kruzliak; Jan Mojzis; Desanka Vybohova; Marian Adamkov; Karina Jasek; Zora Lasabova; Pavol Zubor; Silvia Fialova; Svetlana Dokupilova; Peter Solar; Martin Pec; Katarina Adamicova; Jan Danko; Mariusz Adamek; Dietrich Busselberg
Journal:  J Cell Mol Med       Date:  2017-05-19       Impact factor: 5.310

5.  Prognostic role of lymphatic vessel density and lymphovascular invasion in chemotherapy-naive and chemotherapy-treated patients with invasive breast cancer.

Authors:  Joanna A Niemiec; Agnieszka Adamczyk; Aleksandra Ambicka; Anna Mucha-Małecka; Wojciech M Wysocki; Beata Biesaga; Marek Ziobro; Ida Cedrych; Aleksandra Grela-Wojewoda; Małgorzata Domagała-Haduch; Joanna Wysocka; Janusz Ryś; Beata Sas-Korczyńska
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

6.  Impact of SOX18 expression in cancer cells and vessels on the outcome of invasive ductal breast carcinoma.

Authors:  Bartosz Pula; Mateusz Olbromski; Andrzej Wojnar; Agnieszka Gomulkiewicz; Wojciech Witkiewicz; Maciej Ugorski; Piotr Dziegiel; Marzena Podhorska-Okolow
Journal:  Cell Oncol (Dordr)       Date:  2013-09-25       Impact factor: 6.730

7.  Lymphangiogenesis and Axillary Lymph Node Metastases Correlated with VEGF-C Expression in Two Immunocompetent Mouse Mammary Carcinoma Models.

Authors:  Yuko Ito; Masa-Aki Shibata; Nabil Eid; Junji Morimoto; Yoshinori Otsuki
Journal:  Int J Breast Cancer       Date:  2011-10-19

8.  Angiotensin II type 1 receptor (AT-1R) expression correlates with VEGF-A and VEGF-D expression in invasive ductal breast cancer.

Authors:  Aleksandra Jethon; Bartosz Pula; Aleksandra Piotrowska; Andrzej Wojnar; Janusz Rys; Piotr Dziegiel; Marzena Podhorska-Okolow
Journal:  Pathol Oncol Res       Date:  2012-05-12       Impact factor: 3.201

9.  Vascular Endothelial Growth Factor expression in peripheral blood of patients with pregnancy induced hypertension syndrome and its clinical significance.

Authors:  Yanfang Ren; Huiling Wang; Haixia Qin; Jun Yang; Yuhong Wang; Shan Jiang; Ying Pan
Journal:  Pak J Med Sci       Date:  2014-05       Impact factor: 1.088

10.  High lymphatic vessel density and presence of lymphovascular invasion both predict poor prognosis in breast cancer.

Authors:  Song Zhang; Dong Zhang; Mingfu Gong; Li Wen; Cuiwei Liao; Liguang Zou
Journal:  BMC Cancer       Date:  2017-05-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.